GSK plc (NYSE:GSK) Shares Acquired by New Wave Wealth Advisors LLC

New Wave Wealth Advisors LLC grew its stake in shares of GSK plc (NYSE:GSK) by 13.2% in the 4th quarter, Holdings Channel.com reports. The fund owned 10,524 shares of the pharmaceutical company’s stock after purchasing an additional 1,226 shares during the quarter. New Wave Wealth Advisors LLC’s holdings in GSK were worth $356,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Kempner Capital Management Inc. grew its holdings in GSK by 142.7% during the 4th quarter. Kempner Capital Management Inc. now owns 183,080 shares of the pharmaceutical company’s stock worth $6,192,000 after acquiring an additional 107,648 shares in the last quarter. Cibc World Market Inc. grew its holdings in GSK by 8.7% during the 4th quarter. Cibc World Market Inc. now owns 344,519 shares of the pharmaceutical company’s stock worth $11,652,000 after acquiring an additional 27,434 shares in the last quarter. Crews Bank & Trust acquired a new position in GSK during the 4th quarter worth $26,000. OLD National Bancorp IN grew its holdings in GSK by 13.6% during the 4th quarter. OLD National Bancorp IN now owns 11,106 shares of the pharmaceutical company’s stock worth $376,000 after acquiring an additional 1,332 shares in the last quarter. Finally, Manning & Napier Advisors LLC grew its holdings in GSK by 33.3% during the 4th quarter. Manning & Napier Advisors LLC now owns 200,000 shares of the pharmaceutical company’s stock worth $6,764,000 after acquiring an additional 50,000 shares in the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on GSK shares. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and decreased their price target for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, StockNews.com lowered shares of GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Six research analysts have rated the stock with a hold rating, one has given a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, GSK presently has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Trading Up 0.8 %

Shares of NYSE:GSK opened at $35.35 on Friday. The company has a market cap of $73.27 billion, a PE ratio of 22.96, a P/E/G ratio of 1.37 and a beta of 0.63. The company’s 50-day moving average price is $34.04 and its 200 day moving average price is $37.71. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.